These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18328639)

  • 1. Abuse liability assessment of atomoxetine in a drug-abusing population.
    Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
    Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
    Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.
    Heil SH; Holmes HW; Bickel WK; Higgins ST; Badger GJ; Laws HF; Faries DE
    Drug Alcohol Depend; 2002 Jul; 67(2):149-56. PubMed ID: 12095664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
    Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.
    Wee S; Woolverton WL
    Drug Alcohol Depend; 2004 Sep; 75(3):271-6. PubMed ID: 15283948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
    Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
    Gasior M; Bergman J; Kallman MJ; Paronis CA
    Neuropsychopharmacology; 2005 Apr; 30(4):758-64. PubMed ID: 15526000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
    Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM
    J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
    Bizot JC; David S; Trovero F
    Neurosci Lett; 2011 Feb; 489(1):20-4. PubMed ID: 21129437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
    Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
    J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
    Zacny JP
    Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.